Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -1.80% and Operating profit at -22.63% over the last 5 years
- OPERATING CASH FLOW(Y) Lowest at CNY 300.55 MM
- ROCE(HY) Lowest at 4.73%
- DEBT-EQUITY RATIO (HY) Highest at -18.46 %
2
Risky -
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,995 Million (Mid Cap)
40.00
NA
1.65%
-0.24
-3.30%
1.45
Revenue and Profits:
Net Sales:
582 Million
(Quarterly Results - Mar 2026)
Net Profit:
86 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.65%
0%
-7.65%
6 Months
-15.39%
0%
-15.39%
1 Year
-13.06%
0%
-13.06%
2 Years
-35.42%
0%
-35.42%
3 Years
-37.53%
0%
-37.53%
4 Years
-57.94%
0%
-57.94%
5 Years
-79.98%
0%
-79.98%
Guangzhou Wondfo Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.80%
EBIT Growth (5y)
-22.63%
EBIT to Interest (avg)
29.85
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.24
Sales to Capital Employed (avg)
0.44
Tax Ratio
9.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.13%
ROE (avg)
17.16%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
1.64
EV to EBIT
35.85
EV to EBITDA
18.89
EV to Capital Employed
1.79
EV to Sales
3.11
PEG Ratio
NA
Dividend Yield
1.46%
ROCE (Latest)
4.99%
ROE (Latest)
4.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
581.70
396.70
46.63%
Operating Profit (PBDIT) excl Other Income
100.30
-179.50
155.88%
Interest
7.40
7.00
5.71%
Exceptional Items
6.70
-11.40
158.77%
Consolidate Net Profit
86.10
-196.10
143.91%
Operating Profit Margin (Excl OI)
172.40%
-627.40%
79.98%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 46.63% vs -10.75% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 143.91% vs -207.37% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,080.90
3,057.00
-31.93%
Operating Profit (PBDIT) excl Other Income
135.10
862.30
-84.33%
Interest
33.20
32.30
2.79%
Exceptional Items
3.70
26.30
-85.93%
Consolidate Net Profit
-69.70
565.20
-112.33%
Operating Profit Margin (Excl OI)
-64.10%
191.60%
-25.57%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -31.93% vs 10.83% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -112.33% vs 15.96% in Dec 2024
About Guangzhou Wondfo Biotech Co., Ltd. 
Guangzhou Wondfo Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






